TNF-α
Tumor necrosis factor alpha (TNF-α), belongs to the superfamily of TNF/TNFR cytokine superfamily, is a type II transmembrane protein (mTNF) with an intracellular N terminus that is produced as 26 kDa membrane-bound cytokine comprised of 233 amino acids. TNF-α also exists as a soluble cytokine (sTNF), which is a non-covalently bound 17 kDa trimer (157 amino acids with a 76 amino acid presequence) resulted from the cleavage of mTNF by TNF-α converting enzyme (TACE). Two distinct and highly affinitive receptors of TNF-α have been identified, including TNFR55 (a 55 kDa receptor) and TNFR75 (a 75 kDa receptor), through which multiple activities of TNF-α are mediated. TNF-α has been found to be involved in maintenance and homeostasis of the immune system, inflammation and host defence as well as a variety of pathological processes.
Products for TNF-α
- Cat.No. Product Name Information
- GC63231 TNF-α-IN-2 TNF-α-IN-2 is a potent and orally active inhibitor of tumor necrosis factor alpha (TNFα), with an IC50 of 25 nM in the HTRF assay.
- GC68385 TNF-α-IN-6
- GC31905 TNF-α-IN-1 TNF-α-IN-1 is a TNF-α inhibitor extracted from patent US20030096841A1, compound example I-7.
- GC38868 TRAF-STOP inhibitor 6877002 TRAF-STOP inhibitor 6877002, is a selective inhibitor of CD40-TRAF6 interaction, compound VII, shows inhibition of NF-κB activation in RAW cells, extracted from patent WO2014033122A1.
- GC48195 trans-trismethoxy Resveratrol-d4 An internal standard for the quantification of trans-trismethoxy resveratrol
- GC48202 Treprostinil (diethanolamine salt) Treprostinil (UT-15C) diethanolamine is a potent EP2, DP1 and IP agonist with Ki values of 3.6, 4.4, 32.1, 212, 826, 2505 and 4680 nM for EP2, DP1, IP, EP1, EP4, EP3 and FP, respectively.
- GC66460 UCB-5307 UCB-5307 is a potent TNF signaling inhibitor with a KD of 9 nM for human TNFα. UCB-5307 can penetrate the preformed hTNF/hTNFR1 complex.
- GC62346 UCB-9260 UCB-9260, an orally active compound, inhibits TNF signaling by stabilising an asymmetric form of the trimer.
- GC61533 UTL-5g UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects.
-
GC70104
Utomilumab
Utomilumab (PF 05082566) is a humanized IgG2 mAb agonist that targets the T cell co-stimulatory receptor 4-1BB/CD137. Utomilumab can be used in research for relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin's lymphomas (NHL).
- GC64839 Varlilumab Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity.